BASEL, Switzerland,
Feb. 28 /PRNewswire/ - Neuro-Biotech
Corp. (PINKSHEET: MRES) (OTCQB: MRES) is pleased to provide its
shareholders updates about the due diligence process and the
conditions of the unsolicited offer. As of Friday February 25, all the conditions required
by the parties in order to complete their due diligence have been
met:
- AURIC Pharma Science has provided financial statements proving
its ability to complete the purchase.
- AURIC Pharma Science has provided detailed distribution network
of its products and services.
- Neuro-Biotech Corp.has provided patent information on all its
exclusive products and services.
- Neuro-Biotech Corp. has provided all previous and effected
purchase orders, as well as future pending orders.
Neuro-Biotech management has decided to publish
some of this information directly on its website in order for the
shareholder to access it easily.
Management would also like to announce that
management is expecting to complete it's diligence process by the
end of the day on March 4, 2011.
For more information on Neuro-Biotech Corp or to
contact a company representative, please visit:
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
SOURCE Neuro-Biotech Corp.
Copyright . 28 PR Newswire